ReviewCurrent HIV/AIDS reports2026
Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges.
Review in Current HIV/AIDS reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewLong-acting (LA) antiretroviral therapy (ART) is rapidly revolutionizing the landscape of HIV treatment. Clinical trials for injectable cabotegravir/rilpivirine (CAB/RPV) only included certain populations, limiting FDA approval to a subset of people with HIV; frontline medical staff and community members (inclusive of PWH) employed resourcefulness, collaboration, and advocacy to maximize access. However, significant implementation hurdles have constrained uptake, and research about clinical outcomes in PWH who initiate LA-ART with viremia or adherence challenges is nascent. RECENT
findingsPWH who initiate LAI-ART with viremia, including those with adherence challenges, achieve and maintain viral suppression (VS) at rates similar to PWH who initiate with VS. LAI-ART, in combination with appropriate support and programming, can increase access to ART in PWH with viremia and/or adherence challenges. The overall cost, in terms of dollars and person-time, makes implementation challenging. Additional funding mechanisms are needed, alongside innovative research regarding effective programs and care delivery models, to maximize implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.